- 19 Downloads
An event is serious (FDA MedWatch definition) when the patient outcome is:
* congenital anomaly
* requires intervention to prevent permanent impairment or damage
A 76-year-old man developed progressive metastatic Merkel cell carcinoma (MCC), shortness of breath and right pleural effusion following treatment with alemtuzumab and fludarabine.
The man was diagnosed with chronic lymphocytic leukaemia (CLL) in 1998. Four years later, he started receiving combination therapy with alemtuzumab and fludarabine [route and dosage not stated] following appearance of night sweats and rapid doubling of lymphocyte count. He was concomitantly taking oral B12 supplementation along with various other medications. Initially, positive results were seen. However, he developed persistent hypogammaglobulinemia and profound lymphopenia that continued for over a decade. In 2007, a second cutaneous melanoma developed on a different...
- Yu KK, et al. Rapidly Fatal Dissemination of Merkel Cell Carcinoma in a Patient Treated with Alemtuzumab for Chronic Lymphocytic Leukemia. Connecticut Medicine 80: 353-8, No. 6, Jun-Jul 2016. Available from: URL: http://connmed.csms.org/i/687057-june-july-2016/34 - USAPubMedGoogle Scholar